Drug Trial Radar · NCT00641914
Inhaled Steroid Treatment as Regular Therapy in Early Asthma
Last checked: Nov 19, 2026Latest source record: Mar 25, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,800
Planned (sponsor's estimate)
Start
Oct 1996
Primary completion
Feb 2003
Study completion Feb 2003
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 24, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study of the effect of the early treatment with Pulmicort of newly diagnosed asthma. Patients will receive either Pulmicort or a non-active treatment for three years. Neither patients or investigators will be aware of the treatment received. After three years of treatment all patients will receive Pulmicort for 2 further years.
Conditions
- Asthma
Interventions
budesonideDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Severe asthma related events (SARE) (part A); post-bronchodilator FEV1 % of predicted normal (part B)Time frame: At week 6 and12, and every 3 months thereafter
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.